Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls

Sean P. Collins, MD, PhD, presented “Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.

How to cite: Collins, Sean P. “Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls.” October 8, 2024. Accessed Jul 2025. https://grandroundsinurology.com/radiation-therapy-planning-using-advanced-imaging-pearls-and-pitfalls-2/

Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls – Summary

This 7-minute presentation by Sean Collins, MD, PhD, a radiation oncologist at Tampa General Hospital, provides an in-depth exploration of POSLUMA, a new PSMA-specific PET imaging agent approved in May 2023 for prostate cancer.

Dr. Collins presents clinical scenarios demonstrating POSLUMA’s impact on staging and treatment planning. These findings can lead to significant management changes, including adjusted radiation doses, expanded fields, or shifts to systemic therapy for widespread disease.

Dr. Collins highlights challenges, such as renal excretion, and potential solutions and treatment. Importantly, POSLUMA exhibits lower bladder activity than other renal-cleared PSMA agents, potentially reducing risks like misidentification of ureters as lymph nodes.

Dr. Collins underscores the agent’s utility in refining treatment plans, especially for high-risk and recurrent prostate cancer.

The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.